Riboflavin for Glutamate Reduction in Alcohol Withdrawal (RGRAW)
Primary Purpose
Alcohol Withdrawal, Nutrition Disorders, Alcohol Use Disorder
Status
Unknown status
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Riboflavin
Placebo
Sponsored by
About this trial
This is an interventional basic science trial for Alcohol Withdrawal focused on measuring Glutamate, Riboflavin
Eligibility Criteria
Inclusion Criteria:
- Adult veterans ages 18-65
- Admitted to the inpatient psychiatric unit at the Portland VA
- Determine by admitting physician to be currently in or at risk of alcohol withdrawal during admission
- Placed on the CIWA-AR protocol
- Willing to provide informed consent/HIPAA authorization and accept randomization
- Willing to ingest three capsules/day
- Willing to provide daily blood samples H) Fluent in English
Exclusion Criteria:
- Known allergy to ingredients of riboflavin, capsules, or placebo ingredients
- Taking any medication acting primarily on Glu receptors (e.g. memantine) or GABA receptors (benzodiazepines) at baseline
- Unable to swallow capsules
- Actively in withdrawal from substances other than alcohol
- Unable to provide full informed consent/HIPAA authorization
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Riboflavin
Placebo
Arm Description
Participants in this group will receive 100mg riboflavin TID during study participation.
Participants in this group will receive inert placebo capsules TID during study participation.
Outcomes
Primary Outcome Measures
Peripheral blood glutamate level at baseline
measured using high performance liquid chromatography (HPLC)
Peripheral blood glutamate level, day 2
measured using high performance liquid chromatography (HPLC)
Peripheral blood glutamate level, day 4
measured using high performance liquid chromatography (HPLC)
Peripheral blood glutamate level, day 6
measured using high performance liquid chromatography (HPLC)
Peripheral blood glutamate level, day 8
measured using high performance liquid chromatography (HPLC)
Peripheral blood glutamate level, day 10
measured using high performance liquid chromatography (HPLC)
Secondary Outcome Measures
Baseline Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores
The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal. It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g. benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
Day 2: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores
The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal. It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g. benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
Day 3: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores
The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal. It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g. benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
Day 4: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores
The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal. It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g. benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
Day 5: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores
The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal. It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g. benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
Day 6: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores
The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal. It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g. benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
Day 7: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores
The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal. It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g. benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
Day 8: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores
The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal. It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g. benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
Day 9: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores
The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal. It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g. benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
Day 10: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores
The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal. It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g. benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
Baseline: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration
As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met. That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines. This data is collected as standard of care, but will be used as a secondary outcome for this study.
Day 2: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration
As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met. That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines. This data is collected as standard of care, but will be used as a secondary outcome for this study.
Day 3: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration
As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met. That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines. This data is collected as standard of care, but will be used as a secondary outcome for this study.
Day 4: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration
As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met. That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines. This data is collected as standard of care, but will be used as a secondary outcome for this study.
Day 5: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration
As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met. That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines. This data is collected as standard of care, but will be used as a secondary outcome for this study.
Day 6: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration
As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met. That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines. This data is collected as standard of care, but will be used as a secondary outcome for this study.
Day 7: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration
As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met. That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines. This data is collected as standard of care, but will be used as a secondary outcome for this study.
Day 8: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration
As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met. That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines. This data is collected as standard of care, but will be used as a secondary outcome for this study.
Day 9: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration
As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met. That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines. This data is collected as standard of care, but will be used as a secondary outcome for this study.
Day 10: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration
As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met. That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines. This data is collected as standard of care, but will be used as a secondary outcome for this study.
Baseline: Generalized Anxiety Disorder - 7 (GAD7) scale
A standardized measure of anxiety over the previous 2 weeks. Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
Day 2: Generalized Anxiety Disorder - 7 (GAD7) scale
A standardized measure of anxiety over the previous 2 weeks. Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
Day 3: Generalized Anxiety Disorder - 7 (GAD7) scale
A standardized measure of anxiety over the previous 2 weeks. Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
Day 4: Generalized Anxiety Disorder - 7 (GAD7) scale
A standardized measure of anxiety over the previous 2 weeks. Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
Day 5: Generalized Anxiety Disorder - 7 (GAD7) scale
A standardized measure of anxiety over the previous 2 weeks. Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
Day 6: Generalized Anxiety Disorder - 7 (GAD7) scale
A standardized measure of anxiety over the previous 2 weeks. Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
Day 7: Generalized Anxiety Disorder - 7 (GAD7) scale
A standardized measure of anxiety over the previous 2 weeks. Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
Day 8: Generalized Anxiety Disorder - 7 (GAD7) scale
A standardized measure of anxiety over the previous 2 weeks. Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
Day 9: Generalized Anxiety Disorder - 7 (GAD7) scale
A standardized measure of anxiety over the previous 2 weeks. Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
Day 10: Generalized Anxiety Disorder - 7 (GAD7) scale
A standardized measure of anxiety over the previous 2 weeks. Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
Baseline: The Alcohol Craving Questionnaire-Revised (ACQ-R)
A brief, reliable, and validated measure of alcohol craving. Scores range from 1-7 with higher scores indicating stronger alcohol cravings
Day 2: The Alcohol Craving Questionnaire-Revised (ACQ-R)
A brief, reliable, and validated measure of alcohol craving. Scores range from 1-7 with higher scores indicating stronger alcohol cravings
Day 3: The Alcohol Craving Questionnaire-Revised (ACQ-R)
A brief, reliable, and validated measure of alcohol craving. Scores range from 1-7 with higher scores indicating stronger alcohol cravings
Day 4: The Alcohol Craving Questionnaire-Revised (ACQ-R)
A brief, reliable, and validated measure of alcohol craving. Scores range from 1-7 with higher scores indicating stronger alcohol cravings
Day 5: The Alcohol Craving Questionnaire-Revised (ACQ-R)
A brief, reliable, and validated measure of alcohol craving. Scores range from 1-7 with higher scores indicating stronger alcohol cravings
Day 6: The Alcohol Craving Questionnaire-Revised (ACQ-R)
A brief, reliable, and validated measure of alcohol craving. Scores range from 1-7 with higher scores indicating stronger alcohol cravings
Day 7: The Alcohol Craving Questionnaire-Revised (ACQ-R)
A brief, reliable, and validated measure of alcohol craving. Scores range from 1-7 with higher scores indicating stronger alcohol cravings
Day 8: The Alcohol Craving Questionnaire-Revised (ACQ-R)
A brief, reliable, and validated measure of alcohol craving. Scores range from 1-7 with higher scores indicating stronger alcohol cravings
Day 9: The Alcohol Craving Questionnaire-Revised (ACQ-R)
A brief, reliable, and validated measure of alcohol craving. Scores range from 1-7 with higher scores indicating stronger alcohol cravings
Day 10: The Alcohol Craving Questionnaire-Revised (ACQ-R)
A brief, reliable, and validated measure of alcohol craving. Scores range from 1-7 with higher scores indicating stronger alcohol cravings
Baseline: The Daily Assessment of Symptoms -Anxiety (DAS-A)
A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours. Scores range from 0-80, with a higher score indicating more symptoms of anxiety
Day 2: The Daily Assessment of Symptoms -Anxiety (DAS-A)
A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours. Scores range from 0-80, with a higher score indicating more symptoms of anxiety
Day 3: The Daily Assessment of Symptoms -Anxiety (DAS-A)
A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours. Scores range from 0-80, with a higher score indicating more symptoms of anxiety
Day 4: The Daily Assessment of Symptoms -Anxiety (DAS-A)
A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours. Scores range from 0-80, with a higher score indicating more symptoms of anxiety
Day 5: The Daily Assessment of Symptoms -Anxiety (DAS-A)
A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours. Scores range from 0-80, with a higher score indicating more symptoms of anxiety
Day 6: The Daily Assessment of Symptoms -Anxiety (DAS-A)
A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours. Scores range from 0-80, with a higher score indicating more symptoms of anxiety
Day 7: The Daily Assessment of Symptoms -Anxiety (DAS-A)
A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours. Scores range from 0-80, with a higher score indicating more symptoms of anxiety
Day 8: The Daily Assessment of Symptoms -Anxiety (DAS-A)
A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours. Scores range from 0-80, with a higher score indicating more symptoms of anxiety
Day 9: The Daily Assessment of Symptoms -Anxiety (DAS-A)
A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours. Scores range from 0-80, with a higher score indicating more symptoms of anxiety
Day 10: The Daily Assessment of Symptoms -Anxiety (DAS-A)
A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours. Scores range from 0-80, with a higher score indicating more symptoms of anxiety
Full Information
NCT ID
NCT04232800
First Posted
January 13, 2020
Last Updated
September 27, 2021
Sponsor
Oregon Health and Science University
1. Study Identification
Unique Protocol Identification Number
NCT04232800
Brief Title
Riboflavin for Glutamate Reduction in Alcohol Withdrawal
Acronym
RGRAW
Official Title
Riboflavin for Glutamate Reduction in Alcohol Withdrawal
Study Type
Interventional
2. Study Status
Record Verification Date
September 2021
Overall Recruitment Status
Unknown status
Study Start Date
December 1, 2021 (Anticipated)
Primary Completion Date
August 25, 2022 (Anticipated)
Study Completion Date
October 25, 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Oregon Health and Science University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This RCT intends to investigate the use of oral Riboflavin (Vitamin B2) for reduction of blood glutamate levels in the setting of acute alcohol withdrawal. Participants will be patients admitted to an inpatient hospital unit diagnosed with acute alcohol withdrawal. In addition to receiving care as usual, they will be randomized to receive either 100mg TID riboflavin or an identically dosed placebo. The primary outcome measure will be blood glutamate levels. Secondary outcomes will include measures of alcohol withdrawal and alcohol craving. The investigators hypothesize that those in the riboflavin group will have lower blood levels of glutamate, as well as decreased symptoms of alcohol withdrawal.
Detailed Description
General Investigational Plan
Hypotheses:
Aim 1: Measure the impact of daily oral riboflavin supplementation on blood Glu levels.
Hypothesis 1: Patients receiving riboflavin will have significant reductions in blood Glu levels, as compared to placebo.
Aim 2: Observe the impact of oral riboflavin on CIWA-AR scale scoring. Hypothesis 2: Riboflavin will significantly reduce the active group's CIWA-AR scores, and will result in fewer symptom triggered benzodiazepine doses, as compared to placebo.
Plan: The proposed study would apply a recently identified method using vitamin B2 (riboflavin) to reduce excess brain Glu activity in veterans in acute alcohol withdrawal. This method of "glutamate scavenging", was identified in a 2018 as a way to reduce glutamate associated brain damage which typically occurs after stroke. When tested in human patients immediately following stroke, the intervention demonstrated efficacy through better structural and functional outcomes when compared to placebo. Improvements persisted at 3 months after the initial stroke, and were not associated with any known side effects. Administration of riboflavin quickly decreases Glu levels in both the blood and brain, as measured using chromatography and Magnetic Resonance Imaging (MRI), respectively. As riboflavin's Glu reducing properties have just been discovered, this method has only been applied to the treatment of stroke, and has yet to be studied outside of the field of neurology. Further, oral riboflavin has not been investigated as a method of glutamate reduction. The hyperglutamatergic state in patients with alcohol withdrawal provides one opportunity for such an investigation, one that may lead to future studies improving treatments of alcohol withdrawal. Chronic, as well as acute alcohol users have both elevated extracellular glutamate as well as changes to glutamate receptors and transporters. These changes appear play a role in the rewarding effects of alcohol, and contribute to the symptoms of withdrawal. A positive correlation exists between CSF levels of glutamate and the severity of alcohol dependence, and patients in acute withdrawal have measurably increased levels of glutamate in their peripheral blood. During early withdrawal, elevated glutamate levels have been observed in the hippocampus and anterior cingulate cortex, returning to normal 3 days after symptom resolution. Given this information, riboflavin may provide a safe, effective, and affordable intervention to normalize the hyperglutamatergic state associated with alcohol withdrawal. The proposed study would investigate this hypothesis in patients admitted to the inpatient psychiatry unit in acute alcohol withdrawal.
Methods: Participants would be recruited on the inpatient psychiatry unit as they were admitted. The primary teams/on call residents would be asked to page a study member if a patient was admitted on the standard protocol for alcohol withdrawal: the Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-Ar). The study coordinator would consent the patient, and they would be randomized to either the placebo or riboflavin group. They would then receive TID oral dosing of either 100mg riboflavin or placebo, in addition to treatment as usual. The primary outcome would be daily blood glutamate levels, obtained with the normal morning labs. Secondary outcomes would CIWA scores, number of symptom-triggered benzodiazepines given, anxiety, and alcohol craving scores (using standardized measures).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alcohol Withdrawal, Nutrition Disorders, Alcohol Use Disorder
Keywords
Glutamate, Riboflavin
7. Study Design
Primary Purpose
Basic Science
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
Participants will be randomized to receive either riboflavin or an identical inert placebo.
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Treatment and placebo capsules will be identical, and will be identified with each participants unique randomization number provided by the VA pharmacy. This will ensure blinding until study completion. Neither participants nor any study or treatment team members will know the group allocation.
Allocation
Randomized
Enrollment
40 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Riboflavin
Arm Type
Experimental
Arm Description
Participants in this group will receive 100mg riboflavin TID during study participation.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Participants in this group will receive inert placebo capsules TID during study participation.
Intervention Type
Drug
Intervention Name(s)
Riboflavin
Other Intervention Name(s)
Vitamin B2
Intervention Description
The intervention will consist of 100mg riboflavin (vitamin B2) given in three time daily dosing.
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
An inert, standard placebo in identical capsules to primary intervention.
Primary Outcome Measure Information:
Title
Peripheral blood glutamate level at baseline
Description
measured using high performance liquid chromatography (HPLC)
Time Frame
Will occur on the day of enrollment in the study
Title
Peripheral blood glutamate level, day 2
Description
measured using high performance liquid chromatography (HPLC)
Time Frame
Will occur on day 2 of the study
Title
Peripheral blood glutamate level, day 4
Description
measured using high performance liquid chromatography (HPLC)
Time Frame
Will occur on day 4 of the study
Title
Peripheral blood glutamate level, day 6
Description
measured using high performance liquid chromatography (HPLC)
Time Frame
Will occur on day 6 of the study
Title
Peripheral blood glutamate level, day 8
Description
measured using high performance liquid chromatography (HPLC)
Time Frame
Will occur on day 8 of the study
Title
Peripheral blood glutamate level, day 10
Description
measured using high performance liquid chromatography (HPLC)
Time Frame
Will occur on day 10 of the study
Secondary Outcome Measure Information:
Title
Baseline Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores
Description
The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal. It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g. benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
Time Frame
Will occur on the day of enrollment in the study
Title
Day 2: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores
Description
The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal. It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g. benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
Time Frame
Will occur on the day 2 after randomization (if participant has not yet discharged from the hospital)
Title
Day 3: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores
Description
The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal. It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g. benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
Time Frame
Will occur on the day 3 after randomization (if participant has not yet discharged from the hospital)
Title
Day 4: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores
Description
The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal. It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g. benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
Time Frame
Will occur on the day 4 after randomization (if participant has not yet discharged from the hospital)
Title
Day 5: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores
Description
The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal. It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g. benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
Time Frame
Will occur on the day 5 after randomization (if participant has not yet discharged from the hospital)
Title
Day 6: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores
Description
The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal. It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g. benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
Time Frame
Will occur on the day 6 after randomization (if participant has not yet discharged from the hospital)
Title
Day 7: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores
Description
The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal. It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g. benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
Time Frame
Will occur on the day 7 after randomization (if participant has not yet discharged from the hospital)
Title
Day 8: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores
Description
The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal. It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g. benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
Time Frame
Will occur on the day 8 after randomization (if participant has not yet discharged from the hospital)
Title
Day 9: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores
Description
The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal. It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g. benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
Time Frame
Will occur on the day 9 after randomization (if participant has not yet discharged from the hospital)
Title
Day 10: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores
Description
The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal. It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g. benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
Time Frame
Will occur on the day 10 after randomization (if participant has not yet discharged from the hospital)
Title
Baseline: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration
Description
As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met. That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines. This data is collected as standard of care, but will be used as a secondary outcome for this study.
Time Frame
Will occur on the day of enrollment in the study
Title
Day 2: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration
Description
As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met. That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines. This data is collected as standard of care, but will be used as a secondary outcome for this study.
Time Frame
Will occur on the day 2 after randomization (if participant has not yet discharged from the hospital)
Title
Day 3: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration
Description
As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met. That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines. This data is collected as standard of care, but will be used as a secondary outcome for this study.
Time Frame
Will occur on the day 3 after randomization (if participant has not yet discharged from the hospital)
Title
Day 4: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration
Description
As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met. That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines. This data is collected as standard of care, but will be used as a secondary outcome for this study.
Time Frame
Will occur on the day 4 after randomization (if participant has not yet discharged from the hospital)
Title
Day 5: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration
Description
As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met. That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines. This data is collected as standard of care, but will be used as a secondary outcome for this study.
Time Frame
Will occur on the day 5 after randomization (if participant has not yet discharged from the hospital)
Title
Day 6: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration
Description
As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met. That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines. This data is collected as standard of care, but will be used as a secondary outcome for this study.
Time Frame
Will occur on the day 6 after randomization (if participant has not yet discharged from the hospital)
Title
Day 7: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration
Description
As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met. That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines. This data is collected as standard of care, but will be used as a secondary outcome for this study.
Time Frame
Will occur on the day 7 after randomization (if participant has not yet discharged from the hospital)
Title
Day 8: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration
Description
As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met. That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines. This data is collected as standard of care, but will be used as a secondary outcome for this study.
Time Frame
Will occur on the day 8 after randomization (if participant has not yet discharged from the hospital)
Title
Day 9: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration
Description
As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met. That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines. This data is collected as standard of care, but will be used as a secondary outcome for this study.
Time Frame
Will occur on the day 9 after randomization (if participant has not yet discharged from the hospital)
Title
Day 10: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration
Description
As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met. That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines. This data is collected as standard of care, but will be used as a secondary outcome for this study.
Time Frame
Will occur on the day 10 after randomization (if participant has not yet discharged from the hospital)
Title
Baseline: Generalized Anxiety Disorder - 7 (GAD7) scale
Description
A standardized measure of anxiety over the previous 2 weeks. Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
Time Frame
Will occur on the day of enrollment in the study
Title
Day 2: Generalized Anxiety Disorder - 7 (GAD7) scale
Description
A standardized measure of anxiety over the previous 2 weeks. Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
Time Frame
Will occur on the day 2 after randomization (if participant has not yet discharged from the hospital)
Title
Day 3: Generalized Anxiety Disorder - 7 (GAD7) scale
Description
A standardized measure of anxiety over the previous 2 weeks. Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
Time Frame
Will occur on the day 3 after randomization (if participant has not yet discharged from the hospital)
Title
Day 4: Generalized Anxiety Disorder - 7 (GAD7) scale
Description
A standardized measure of anxiety over the previous 2 weeks. Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
Time Frame
Will occur on the day 4 after randomization (if participant has not yet discharged from the hospital)
Title
Day 5: Generalized Anxiety Disorder - 7 (GAD7) scale
Description
A standardized measure of anxiety over the previous 2 weeks. Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
Time Frame
Will occur on the day 5 after randomization (if participant has not yet discharged from the hospital)
Title
Day 6: Generalized Anxiety Disorder - 7 (GAD7) scale
Description
A standardized measure of anxiety over the previous 2 weeks. Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
Time Frame
Will occur on the day 6 after randomization (if participant has not yet discharged from the hospital)
Title
Day 7: Generalized Anxiety Disorder - 7 (GAD7) scale
Description
A standardized measure of anxiety over the previous 2 weeks. Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
Time Frame
Will occur on the day 7 after randomization (if participant has not yet discharged from the hospital)
Title
Day 8: Generalized Anxiety Disorder - 7 (GAD7) scale
Description
A standardized measure of anxiety over the previous 2 weeks. Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
Time Frame
Will occur on the day 8 after randomization (if participant has not yet discharged from the hospital)
Title
Day 9: Generalized Anxiety Disorder - 7 (GAD7) scale
Description
A standardized measure of anxiety over the previous 2 weeks. Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
Time Frame
Will occur on the day 9 after randomization (if participant has not yet discharged from the hospital)
Title
Day 10: Generalized Anxiety Disorder - 7 (GAD7) scale
Description
A standardized measure of anxiety over the previous 2 weeks. Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
Time Frame
Will occur on the day 10 after randomization (if participant has not yet discharged from the hospital)
Title
Baseline: The Alcohol Craving Questionnaire-Revised (ACQ-R)
Description
A brief, reliable, and validated measure of alcohol craving. Scores range from 1-7 with higher scores indicating stronger alcohol cravings
Time Frame
Will occur on the day of enrollment in the study
Title
Day 2: The Alcohol Craving Questionnaire-Revised (ACQ-R)
Description
A brief, reliable, and validated measure of alcohol craving. Scores range from 1-7 with higher scores indicating stronger alcohol cravings
Time Frame
Will occur on the day 2 after randomization (if participant has not yet discharged from the hospital)
Title
Day 3: The Alcohol Craving Questionnaire-Revised (ACQ-R)
Description
A brief, reliable, and validated measure of alcohol craving. Scores range from 1-7 with higher scores indicating stronger alcohol cravings
Time Frame
Will occur on the day 3 after randomization (if participant has not yet discharged from the hospital)
Title
Day 4: The Alcohol Craving Questionnaire-Revised (ACQ-R)
Description
A brief, reliable, and validated measure of alcohol craving. Scores range from 1-7 with higher scores indicating stronger alcohol cravings
Time Frame
Will occur on the day 4 after randomization (if participant has not yet discharged from the hospital)
Title
Day 5: The Alcohol Craving Questionnaire-Revised (ACQ-R)
Description
A brief, reliable, and validated measure of alcohol craving. Scores range from 1-7 with higher scores indicating stronger alcohol cravings
Time Frame
Will occur on the day 5 after randomization (if participant has not yet discharged from the hospital)
Title
Day 6: The Alcohol Craving Questionnaire-Revised (ACQ-R)
Description
A brief, reliable, and validated measure of alcohol craving. Scores range from 1-7 with higher scores indicating stronger alcohol cravings
Time Frame
Will occur on the day 6 after randomization (if participant has not yet discharged from the hospital)
Title
Day 7: The Alcohol Craving Questionnaire-Revised (ACQ-R)
Description
A brief, reliable, and validated measure of alcohol craving. Scores range from 1-7 with higher scores indicating stronger alcohol cravings
Time Frame
Will occur on the day 7 after randomization (if participant has not yet discharged from the hospital)
Title
Day 8: The Alcohol Craving Questionnaire-Revised (ACQ-R)
Description
A brief, reliable, and validated measure of alcohol craving. Scores range from 1-7 with higher scores indicating stronger alcohol cravings
Time Frame
Will occur on the day 8 after randomization (if participant has not yet discharged from the hospital)
Title
Day 9: The Alcohol Craving Questionnaire-Revised (ACQ-R)
Description
A brief, reliable, and validated measure of alcohol craving. Scores range from 1-7 with higher scores indicating stronger alcohol cravings
Time Frame
Will occur on the day 9 after randomization (if participant has not yet discharged from the hospital)
Title
Day 10: The Alcohol Craving Questionnaire-Revised (ACQ-R)
Description
A brief, reliable, and validated measure of alcohol craving. Scores range from 1-7 with higher scores indicating stronger alcohol cravings
Time Frame
Will occur on the day 10 after randomization (if participant has not yet discharged from the hospital)
Title
Baseline: The Daily Assessment of Symptoms -Anxiety (DAS-A)
Description
A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours. Scores range from 0-80, with a higher score indicating more symptoms of anxiety
Time Frame
Will occur on the day of enrollment in the study
Title
Day 2: The Daily Assessment of Symptoms -Anxiety (DAS-A)
Description
A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours. Scores range from 0-80, with a higher score indicating more symptoms of anxiety
Time Frame
Will occur on the day 2 after randomization (if participant has not yet discharged from the hospital)
Title
Day 3: The Daily Assessment of Symptoms -Anxiety (DAS-A)
Description
A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours. Scores range from 0-80, with a higher score indicating more symptoms of anxiety
Time Frame
Will occur on the day 3 after randomization (if participant has not yet discharged from the hospital)
Title
Day 4: The Daily Assessment of Symptoms -Anxiety (DAS-A)
Description
A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours. Scores range from 0-80, with a higher score indicating more symptoms of anxiety
Time Frame
Will occur on the day 4 after randomization (if participant has not yet discharged from the hospital)
Title
Day 5: The Daily Assessment of Symptoms -Anxiety (DAS-A)
Description
A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours. Scores range from 0-80, with a higher score indicating more symptoms of anxiety
Time Frame
Will occur on the day 5 after randomization (if participant has not yet discharged from the hospital)
Title
Day 6: The Daily Assessment of Symptoms -Anxiety (DAS-A)
Description
A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours. Scores range from 0-80, with a higher score indicating more symptoms of anxiety
Time Frame
Will occur on the day 6 after randomization (if participant has not yet discharged from the hospital)
Title
Day 7: The Daily Assessment of Symptoms -Anxiety (DAS-A)
Description
A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours. Scores range from 0-80, with a higher score indicating more symptoms of anxiety
Time Frame
Will occur on the day 7 after randomization (if participant has not yet discharged from the hospital)
Title
Day 8: The Daily Assessment of Symptoms -Anxiety (DAS-A)
Description
A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours. Scores range from 0-80, with a higher score indicating more symptoms of anxiety
Time Frame
Will occur on the day 8 after randomization (if participant has not yet discharged from the hospital)
Title
Day 9: The Daily Assessment of Symptoms -Anxiety (DAS-A)
Description
A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours. Scores range from 0-80, with a higher score indicating more symptoms of anxiety
Time Frame
Will occur on the day 9 after randomization (if participant has not yet discharged from the hospital)
Title
Day 10: The Daily Assessment of Symptoms -Anxiety (DAS-A)
Description
A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours. Scores range from 0-80, with a higher score indicating more symptoms of anxiety
Time Frame
Will occur on the day 10 after randomization (if participant has not yet discharged from the hospital)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Adult veterans ages 18-65
Admitted to the inpatient psychiatric unit at the Portland VA
Determine by admitting physician to be currently in or at risk of alcohol withdrawal during admission
Placed on the CIWA-AR protocol
Willing to provide informed consent/HIPAA authorization and accept randomization
Willing to ingest three capsules/day
Willing to provide daily blood samples H) Fluent in English
Exclusion Criteria:
Known allergy to ingredients of riboflavin, capsules, or placebo ingredients
Taking any medication acting primarily on Glu receptors (e.g. memantine) or GABA receptors (benzodiazepines) at baseline
Unable to swallow capsules
Actively in withdrawal from substances other than alcohol
Unable to provide full informed consent/HIPAA authorization
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Andrew J Hughes, MD
Phone
7014711543
Email
andrew.j.hughes.1@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Brandon Cornejo, MD, PhD
Organizational Affiliation
Oregon Health & Science University, Portland Veterans Health Administration
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Riboflavin for Glutamate Reduction in Alcohol Withdrawal
We'll reach out to this number within 24 hrs